Pfizer, BioNTech say vaccine is 95% effective, EUA submission 'within days'
Pfizer and BioNTech have done the final efficacy analysis for their Phase III Covid-19 trial, and the results confirm the headline-grabbing release from last week: Their vaccine is 95% effective at preventing Covid-19.
They also said the vaccine was 94.5% effective in older adults, mitigating concerns that the first Covid-19 vaccines might not work as well in one of the populations most susceptible to severe disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.